Changing the Paradigm for the Treatment and Development of New Therapies for FSGS

Area of Science:

• Nephrology
• Clinical Pharmacology

Background:

• Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease characterized by proteinuria, edema, nephrotic syndrome, hypertension, and risk of kidney failure.
• Treatment efficacy for FSGS ranges from 25-69%, influenced by therapy specifics, patient factors, cost, and side effects.
• Variability in treatment response is attributed to heterogeneous etiology and molecular mechanisms underlying FSGS.

Purpose of the Study:

• To review therapeutic options for FSGS and highlight challenges in clinical trial design for rare diseases.
• To propose novel clinical trial approaches for efficient drug development in FSGS.
• To simulate and compare classical versus modern trial designs for determining maximum tolerated dose in FSGS.

Main Methods:

• Literature review of FSGS therapeutic options and clinical trial methodologies.
• Analysis of factors contributing to variable treatment response in FSGS.
• Clinical trial simulation comparing traditional and adaptive designs for dose-finding studies.

Main Results:

• Therapeutic efficacy in FSGS shows significant variability (25-69%).
• Classic clinical trial designs may be suboptimal for rare diseases like FSGS due to recruitment challenges and slow timelines.
• Simulations suggest modern adaptive trial designs offer potential efficiencies.

Conclusions:

• FSGS treatment effectiveness is inconsistent, underscoring the need for better therapeutic strategies.
• Novel clinical trial designs, such as adaptive trials, are crucial for advancing drug development in rare kidney diseases.
• Optimized trial designs can improve efficiency and accelerate the identification of effective treatments for FSGS.